DANA-FARBER CANCER INSTITUTE

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1947-01-01

Employees: -

Market Cap: -

Website: http://www.dana-farber.org/

Clinical Trials

Taxotere, Cisplatin and Irinotecan (CPT-11) for Esophagogastric Cancer

Phase 2

Completed

Conditions: Esophageal Cancer
Gastric Cancer
GE Junction Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2009-04-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 54

Registration Number: NCT00165464

Locations: 🇺🇸
Faulkner Hospital, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

Counseling Interventions for BRCA 1/2 Cancer Susceptibility Testing

Not Applicable

Completed

Conditions: Breast Cancer
Ovarian Cancer

Interventions: Procedure: Genetic Counseling
Procedure: Informed Consent Counseling

First Posted Date: 2005-09-14

Last Posted Date: 2012-08-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 150

Registration Number: NCT00165152

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

A Trial of Thalidomide, Celecoxib, Etoposide and Cyclophosphamide in Patients With Relapsed or Progressive Cancer

Phase 2

Completed

Conditions: Neoplasms

First Posted Date: 2005-09-14

Last Posted Date: 2011-07-07

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 20

Registration Number: NCT00165451

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Protein Tyrosine Kinases (PTK) in Multiple Myeloma

Phase 2

Completed

Conditions: Multiple Myeloma

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 10

Registration Number: NCT00165347

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Docetaxel, Estramustine and Short Term Androgen Withdrawal for Patients With a Rising PSA After Local Treatment

Phase 2

Completed

Conditions: Adenocarcinoma of the Prostate
Prostate Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2018-06-25

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 62

Registration Number: NCT00165399

Locations: 🇺🇸
University of Massachusetts Memorial Medical Center-University Campus, Worcester, Massachusetts, United States
🇺🇸
Norris Cotton Cancer Center, Lebanon, New Hampshire, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 2 locations

Combination Chemotherapy, Radiation Therapy and Surgery for Esophageal Cancer

Phase 2

Completed

Conditions: Adenocarcinoma of Esophagus
Squamous Cell Carcinoma of Esophagus

First Posted Date: 2005-09-14

Last Posted Date: 2014-11-10

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 19

Registration Number: NCT00165490

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States

Tamoxifen in the Prevention of Breast Cancer in Hodgkin's Disease Survivors

Not Applicable

Completed

Conditions: Hodgkin's Disease
Breast Cancer

Interventions: Drug: Tamoxifen

First Posted Date: 2005-09-14

Last Posted Date: 2014-07-09

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 29

Registration Number: NCT00165308

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

Extrapleural Pneumonectomy With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Amifostine and Sodium Thiosulfate

Phase 2

Completed

Conditions: Pleural Mesothelioma
Malignant Pleural Mesothelioma

First Posted Date: 2005-09-14

Last Posted Date: 2014-03-27

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 85

Registration Number: NCT00165516

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States

rhEndostatin Protein Involving Pediatric Patients With Cancer

Phase 1

Terminated

Conditions: Solid Tumors

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-28

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 21

Registration Number: NCT00165373

Locations: 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States

Effects of Tibilone on Bone Density, Menopause Symptoms and Breast Density in Women After Prophylactic Oophorectomy

Phase 2

Completed

Conditions: Menopause
Postmenopausal Bone Loss
Breast Cancer

First Posted Date: 2005-09-14

Last Posted Date: 2007-12-21

Lead Sponsor: Dana-Farber Cancer Institute

Target Recruit Count: 50

Registration Number: NCT00165204

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy